Diabetes Case Study: Co-morbidity of Nonadherence

Similar documents
Diabetes Case Study: Co-morbidity of Nonadherence Maureen Dever, MSN, CRNP, PPCNP.BC, CDE PENS 5/18

Understanding Blood Tests

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values

INSULIN ALLERGY OBJECTIVES CASE OF DL

Supplementary materials

DRUG ALLERGIES WT: KG

Learning Objectives. Perioperative SWEET Success

DIABETES MELLITUS. IAP UG Teaching slides

The Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It

Insulin Prior Authorization with optional Quantity Limit Program Summary

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

Case TWO. Vital Signs: Temperature 36.6degC BP 137/89 HR 110 SpO2 97% on Room Air

MHD I SESSION X. Renal Disease

Diabetic Ketoacidosis

MHD I Session VIII Renal Disease November 6, 2013 STUDENT COPY

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

Test Result Reference Range Flag

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Basal Bolus Insulin Therapy Frequently Asked Questions

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

CASE-BASED SMALL GROUP DISCUSSION MHD II

Distinguishing T1D vs. T2D in Childhood: a case report for discussion

Diabetes in Pregnancy

Diabetic Ketoacidosis (DKA) Critical Care Guideline Two Bag System

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:

Documentation Dissection

Insulin Regimens: Hitting Glycemia Targets

Staff at the Nottingham Children s Hospital. Guidelines process.

Complete this CE activity online at ProCE.com/InsulinPart2

Lantus to levemir conversion

Module 5. Understanding Insulin Therapy

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

Guideline for Children with Type 1 or Type 2 Diabetes on Insulin Requiring Surgery or Sedation

Approach to the Young child & Parent with Child with DM Best Structure for Continued Care

A Children s Bedtime Story

13 year old, Saudi, girl known case of : uncontrolled IDDM for 7 years on 1 I.U/kg premix insulin Admitted electively from the clinic with history of

Diabetic Ketoacidosis

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

The York Diabetes Care Model

Learning Objectives. Are you ready for more insulin formulations?

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Clinician Blood Panel Results

Getting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes

CASE-BASED SMALL GROUP DISCUSSION

POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO

Type 1 Diabetes Mellitus in the Adult. Katie Davis & Liz DeJulius KNH 411: Medical Nutrition Therapy I

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

THE CURRENT APPROACH TO T1D IN CHILDREN

NORMAL LABORATORY VALUES FOR CHILDREN

CRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT

Evaluation Report of the Pneumatic Tube Transport System (PEVCO) connecting Dialysis Hospital to. Mubarak Hospital. Dr.

AACN PCCN Review. Endocrine

Type 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications. Alejandro J de la Torre Pediatric Endocrinology 10/17/2014

INSULIN 101: When, How and What

Delta Check Calculation Guide

Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin

CASE-BASED SMALL GROUP DISCUSSION

DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.

Does Adding Examples to the American Society of Anesthesiologists Physical Status Classification Improve Consistency in Assignment to Patients?

DKA : Diabetic Ketoacidosis & HHS: Hyperlgycemic Hyperosmolar Syndrome Protocol. Glycemic Task Force September 2014

Special Situations 1

Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

SMALL ANIMAL SOFT TISSUE CASE-BASED EXAMINATION

RN Diabetes Medication Titration Protocol

associated with serious complications, but reduce occurrences with preventive measures

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Arterial blood gas Capillary blood glucose every hour. Continue to monitor hourly capillary blood glucose as per protocol (See Appendix A and B)

Jenaca Beagley, MSN, APRN, NP-C, CDE Michelle Smith, MSN, APRN, NP-C

COMPLIANCE WITH THIS DOCUMENT IS MANDATORY

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

Arterial blood gas Capillary blood glucose every hour. Continue to monitor hourly capillary blood glucose as per protocol (See Appendix A and B)

Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.

Nph insulin conversion to lantus

123 Are You Providing Evidence-Based Diabetes Care? - Martin

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Epic Labs Orderable As STAT PRIORITY As of 06/22/2016

Comprehensive Diabetes Treatment

Year 1 Peer Based Learning 2018 Renal System

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

ADMELOG, NOVOLIN, NOVOLOG, and FIASP

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Australian and New Zealand College of Veterinary Scientists. Membership Examination. Small Animal Medicine Paper 1

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

ABFM Diabetes SAM Part 4

Diabetic Emergencies: Ketoacidosis and the Hyperglycemic Hyperosmolar State. Adam Bursua, Pharm.D., BCPS

SMALL ANIMAL SOFT TISSUE CASE- BASED EXAMINATION

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016

Cardiovascular History Taking. Dr. Amitesh Aggarwal Assistant Professor Department of Medicine

Physician Orders PEDIATRIC: LEB ED Hx of DKA with Hyperglycemia Plan

Supplementary Appendix

APPENDIX American Diabetes Association. Published online at

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

Type 2 Diabetes Mellitus Insulin Therapy 2012

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

Transcription:

Diabetes Case Study: Co-morbidity of Nonadherence Maureen Dever, MSN, CRNP, PPCNP.BC, CDE PENS 5/18 Comorbidity of Diabetes Case Study Objective: the learner will discuss an underreported comorbidity of diabetes. I have no related conflicts of interest or disclosures. 1

Case Study: KL KL is a 15 year old female diagnosed with Type 1 DM since age 15 months. She is managed on a basal bolus insulin regimen of insulin glargine (Basaglar) and insulin aspart (Novolog ). Father called angry that KL was having swelling of her bilateral lower extremities. She had been seen in the ED the day prior (9/2o/18),for swelling and was not given any treatment. Case Study: KL Had DKA admission on 9/7/17 and had admitted to missing insulin for 2 days prior. A1C was 14.4 on 9/7/17. Since discharge, reports taking all insulin as prescribed, with much improved glycemic control. She returned to the ED on 9/20/18, after she developed swelling in the bilateral lower extremities 1 week after DKA admission. Swelling occurred from the feet to the vulva bilaterally and she reported pain in her ankles and pelvis. 2

Case Study: KL Complained of itching of bilateral lower extremities and had taken 2 Benadryl tablets earlier that day. She denied taking any other medications except insulin, although she had switched brand of insulin glargine from Lantus to Basaglar recently. She reported feeling a little short of breath earlier that day, that had resolved without intervention. Had swelling of her face 3 days ago that resolved without intervention. On 9/7/18 at DKA admission, wt. 59.7kg, - 3.6kg decrease /7months. BMI normal at 80%. Next steps? What differential diagnoses come to mind? What other questions would you ask? What labs or studies would you obtain? What s your diagnosis? What are your concerns for this patient? 3

Differentials Differential diagnoses: Nephrotic syndrome Renal Failure Congestive Heart failure Pleural Effusion Liver Disease And. Normal Chest Xray no pleural effusion Test Results Component Latest Ref Rng & Units Glucose, Pointof-Care 70-106 mg/dl 9/20/2017 9/20/2017 9/20/2017 6:30 PM 8:27 PM 9:12 PM 29 (LL) 65 (L) 4

Other labs Component Latest Ref Rng & Units Sodium 136-145 mmol/l Potassium 3.8-5.4 mmol/l Chloride 98-106 mmol/l Carbon Dioxide 20-26 mmol/l Urea Nitrogen 7-18 mg/dl Creatinine 0.3-0.8 mg/dl Glucose 70-106 mg/dl Calcium 8.4-10.1 mg/dl Total Bilirubin 0.6-1.4 mg/dl Total Protein 6.2-8.1 g/dl Albumin 3.7-5.6 g/dl Alkaline Phosphatase 70-230 U/L Aspartate Aminotransferase 10-30 U/L Alanine Aminotransferase 5-30 U/L Magnesium 1.5-2.5 mg/dl Phosphorus 2.9-5.4 mg/dl 9/20/2017 6:30 PM 143 3.3 (L) 106 31 (H) 7 0.7 34 (LL) 9.1 0.8 6.4 3.7 77 34 (H) 38 (H) 2.2 3.6 Urine Test Results Component Latest Ref Rng & Units POC Urine Glucose mg/dl POC Urine Bilirubin POC Urine Ketones mg/dl POC Urine Specific Gravity 1.003-1.035 POC Urine Blood POC Urine ph 4.8-7.8 POC Urine Protein mg/dl POC Urine Urobilinogen 0.2-1.0 E.U./dL POC Urine Nitrite POC Urine Leukocytes Urine Pregnancy 9/20/2017 1.010 7.0 0.2 5

Diagnosis?? What is the diagnosis? Diagnosis?? Insulin Edema 6

What Is Insulin Edema? Rare under-reported complication of insulin therapy. Presentation varies from mild peripheral edema to cardiac failure and pleural effusion. Although essential for DM, insulin can have adverse effects such as hypoglycemia and weight gain, and rarely generalized or peripheral edema. Also ascites, periorbital and facial edema. In pediatrics, insulin edema is reported more often in female pediatric patients, and patients with a low BMI. When Does Insulin Edema Occur? Which Patients Are Affected? Shortly after the initiation, or re-initiation of intensive insulin therapy and resolves eventually, without direct intervention in many cases. Reported in newly diagnosed T1DM following initiation of insulin therapy T2DM following the initiation of insulin therapy Poorly controlled T1DM following insulin omission, after insulin is re-initiated. Underweight patients on large doses of insulin. 7

So, what is known about Insulin Edema? Under reported, complication of insulin therapy. Severity is variable, most cases being mild. Presents from mild peripheral edema to rarely, cardiac failure and pleural effusion. Pathophysiology of Insulin Edema: Cause is unclear Initial theory-due to rapid retention of tissue fluid secondary to glycogen deposition Possibly due to the loss of albumin from the circulation due to increased transcapillary leakage (but patients with normal albumin levels have been reported) Alterations in renal electrolyte transport 8

Pathophysiology of Insulin Edema Intensive fluid resuscitation in an insulindeficient catabolic state may lead to extravasation of fluid to the subcutaneous tissue, resulting in peripheral edema. May be exacerbated by the increased capillary permeability associated with chronic hyperglycemia. Transient inappropriate hyperaldosteronism has also been suggested to contribute to the fluid retention. Other Reported Cases of Insulin Edema Reported cases of insulin-induced edema in childhood and adolescence are rare Insulin Edema was first reported in 1928 The first pediatric report dates back to 1979, and then tends to be underreported since One reference in 2015, cited 12 pediatric cases described since 1979 9

One reported case of peripheral edema-11 year old girl Bas, VN. Et. al. (2010). Insulin Oedema in Newly Diagnosed Type 1 Diabetes Mellitus. J Clin Res Ped Endo 2010;2(1):46-48. DOI: 10.4274/jcrpe.v2i1.46 One reported case of peripheral edema-14 year old girl Bas, VN. Et. al. (2010). Insulin Oedema in Newly Diagnosed Type 1 Diabetes Mellitus. J Clin Res Ped Endo 2010;2(1):46-48. DOI: 10.4274/jcrpe.v2i1.46 10

Other Reported Cases of Insulin Edema a 19-year-old woman with newly diagnosed Type 1 DM presented with bilateral pleural effusions, ascites and extensive peripheral edema 2 weeks after starting insulin therapy. Significant cardiac disease was excluded, and the massive fluid retention resolved spontaneously with conservative management Reported by Lee, P., Kinsella, J., Borkman, M. & Carter, J. (2007). Bilateral pleural effusions, ascites, and facial and peripheral oedema in a 19 year old woman 2 weeks following commencement of insulin lispro and detemir an unusual presentation of insulin oedema. Diabetic Medicine. Vol 24(11). Intervention- KL NP reviewed this case with Endocrinologist in outpatient clinic and Endo team involved in treating patient in ED the day prior Reassured KL s father that this is a known complication of insulin, particularly after episode of insulin omission, and intensive insulin management is resumed Insulin edema is self limiting. Watch for any signs of shortness of breath, heart racing. Return to ED if this occurs. Continue present insulin management. 11

Outcome of KL s Insulin Edema KL returned to clinic on 10/5/17 with an A1C 7.2 (<5.7, goal of <7.5) with most blood sugars in target range since her discharge from DKA admission No peripheral edema on P/E All edema had resolved without intervention, except elevation of BLE Wt. increased to 62.3kg,normal BMI 80% Conclusion: Comorbidity of Diabetes: Insulin Edema Insulin Edema is a rare and underreported side effect of insulin therapy and should be recognized as a potential patient comorbidity. This self limiting diagnosis should be considered after excluding renal, cardiac, and hepatic causes of edema in a diabetic child. Monitor for shortness of breath, breathing difficulties, or rapid heart rate and refer to ED if this occurs. Nurses managing diabetes patients should be aware of the potential for insulin edema, particularly for new onset T1DM, T2 patients starting insulin, or patients resuming intensive glycemic control with insulin, following a period of insulin omission, or in underweight diabetic patients. 12

References Bas, VN. Et. al. (2010). Insulin Oedema in Newly Diagnosed Type 1 Diabetes Mellitus. J Clin Res Ped Endo 2(1):46-48. Goturo, A, Jain, N, & Lewis, I. (2013). Bilateral cataracts and insulin oedema in a child with type 1 diabetes mellitus. BMJ Case Rep.Feb Lee, P., Kinsella, J., Borkman, M. & Carter, J. (2007). Bilateral pleural effusions, ascites, and facial and peripheral oedema in a 19 year old woman 2 weeks following commencement of insulin lispro and detemir an unusual presentation of insulin oedema. Diabetic Medicine.Vol 24(11). Mamoulakis, D., Bitsori, M., Galanakis, E., Raissaki, M., & Kalmanti, M. (2006). Insulin-induced oedema in children and adolescents. J. Paediatric Child Health Oct;42(10):655-7. Succurro E, Ruffo M, De Sarro G, Gallelli L, Arturi F. (2015). Bilateral lower limbs edema with wooden character induced by insulin glargine treatment. Acta Diabetol. 52(4):809-11 13